BioTrove Cancels IPO

BioTrove Inc., a Woburn, Mass.-based maker of instruments and consumables for genomic analysis, high-throughput screening and molecular diagnostics, has withdrawn registration for a $75 million IPO, citing unfavorable market conditions. It had planned to trade on the Nasdaq, with Piper Jaffray and Lazard Capital Markets serving as co-lead underwriters.

BioTrove has raised over $43 million in VC funding since 2002, from firms like Catalyst Health & Technology Partners (35.1% pre-IPO stake), CB Health Ventures (17.1%), Vox Equity Partners (14.3%), Biofrontier Partners (6.1%), Fletcher Spaght Associates (6.2%) and Pfizer. www.biotrove.com

Leave a Reply

PEHUB Community

Join the 12505 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget